在临床试验中,从现有的中和抗体开发针对Omicron变异的广泛中和抗体
Yongbo Huang1,2, Zhimin Lin1,2, Xueyan Guo1,2
1State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Virology journal
|November 4, 2025
概括
现有的工程抗体显示对SARS-CoV-2 Omicron变异的广泛中和,提供潜在的新的COVID-19治疗方法. 这项研究开发了针对高风险患者的广泛活性单克隆抗体 (mAbs).
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 新出现的SARS-CoV-2 Omicron菌株挑战了现有的中和抗体 (nAbs).
- 经批准的nAbs显示对XBB和BQ.1等变体的疗效降低.
- 迫切需要广泛活性单克隆抗体 (mAbs) 来预防和治疗COVID-19.
研究的目的:
- 调查工程现有的晚期临床试验mAbs.
- 评估针对新型SARS-CoV-2变种的mAbs重定向的可行性.
主要方法:
- 在nAbs P5-22和P14-44.4的基础上构建了体外亲和力成熟库.
- 使用酵母表面显示和流动细胞测量用于抗体查.
- 评估中和功效,结合动力学,以及体内预防/治疗疗效.
主要成果:
- 获得了大致中和前欧米克朗和BA.1/BA.2变种的抗体.
- 一种双特异性抗体对BA.4/BA.5,XBB和BQ1.1.1.进行了增强的中和.
- 双特异性抗体在小鼠模型中显示出强大的体内治疗和预防疗效.
结论:
- 证明了将现有抗体改造为宽频mAbs.的可能性.
- 为COVID-19开发了潜在的治疗或预防药物.
相关概念视频
00:42Cross-reactivity
32.8K
Overview
32.8K
01:29Immune Response Against Viral Pathogens
1.7K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.7K